Short answer: SS-31, elamipretide, MTP-131 and Bendavia are different names for the same tetrapeptide. In 2025 the US Food and Drug Administration granted accelerated approval to elamipretide, under the brand name Forzinity, for a rare mitochondrial disease called Barth syndrome. That makes SS-31 unusual among peptides sold for research: it has a licensed pharmaceutical form with a defined indication, and a research-grade vial is not that product. This guide sorts out the names, explains the chemistry and mechanism, lists similar peptides, and summarises what the clinical work does and does not show. It is educational, for laboratory readers, and not use advice.
One molecule, four names
Catalogues and papers use different labels for the same compound, which is the source of many search queries such as “what is another name for SS-31”.
- SS-31: the laboratory code. “SS” refers to the Szeto-Schiller peptides, a family of aromatic-cationic tetrapeptides designed by Hazel Szeto and Peter Schiller.
- MTP-131: the code used by the developer in early clinical work.
- Bendavia: an earlier proprietary name.
- Elamipretide: the International Nonproprietary Name, used in clinical literature and regulatory documents.
- Forzinity: the US brand name for the approved formulation.
Chemically, SS-31 is D-Arg-Dmt-Lys-Phe-NH₂, where Dmt is 2′,6′-dimethyltyrosine. The D-amino acid and the dimethylated tyrosine make it more resistant to peptidases, and the alternating basic and aromatic residues give it its characteristic charge and membrane behaviour. Our overview of SS-31 in research and the entry for SS-31 for laboratory research describe the compound as supplied.
How it is thought to work
The design idea, described in Szeto (AAPS Journal, 2006) under the heading mitochondria-targeted peptide antioxidants, is that a small cationic peptide can cross membranes and accumulate at the inner mitochondrial membrane. The 2018 clinical paper by Karaa and colleagues describes elamipretide as an aromatic-cationic tetrapeptide that readily penetrates cell membranes and transiently localises to the inner mitochondrial membrane where it associates with cardiolipin. Cardiolipin is a phospholipid that is particularly abundant in that membrane and important for the organisation of the respiratory chain. The FDA’s description of the approved product is similar: a mitochondrial cardiolipin binder.
Several points of caution apply. A proposed mechanism in a review is a hypothesis, not a proof, and mitochondrial biology is hard to measure in intact systems. The “antioxidant” label used in early papers has also been supplemented by other proposals about membrane structure and respiratory function. A careful laboratory report should state which mechanism it is testing rather than assume one.
Similar peptides and related approaches
People ask “what peptide is similar to SS-31”. The honest answer depends on what “similar” means.
- Structurally similar: other Szeto-Schiller analogues, such as SS-20 and SS-02, which share the aromatic-cationic design but differ in sequence and potency. They are mostly found in the research literature rather than in catalogues.
- Mitochondrial-derived peptides: a different class, encoded in mitochondrial DNA, and discussed in our guides on humanin and MOTS-c. They are naturally occurring signalling peptides, whereas SS-31 is a synthetic design.
- Other mitochondria-targeted approaches: small molecules built around a lipophilic cation, which are not peptides.
None of these is a substitute for another, and similarity in a keyword is not similarity in mechanism. A comparative experiment should state the hypothesis that makes two compounds comparable.
What the clinical evidence shows
SS-31 has more clinical data than most research peptides, which makes it a good test case for reading evidence carefully.
The MMPOWER trial in primary mitochondrial myopathy
Karaa et al. (Neurology, 2018) reported a randomised, double-blind, placebo-controlled phase I/II trial of intravenous elamipretide in 36 adults with genetically confirmed primary mitochondrial myopathy. The primary efficacy measure was the change in distance walked in the six-minute walk test after five days. The authors reported that the highest dose group walked a mean of 64.5 m farther at day 5 compared with 20.4 m in the placebo group (p = 0.053), with a dose-dependent increase (p = 0.014), and an adjusted analysis that was nominally significant. No significant differences were observed in other efficacy and safety endpoints. This is a small early-phase study with a borderline primary result, and it should be read that way.
Barth syndrome and the FDA decision
Thompson et al. (Genetics in Medicine, 2024) reported 168-week open-label extension results on the long-term efficacy and safety of elamipretide in patients with Barth syndrome, a rare, life-limiting mitochondrial disease. On 19 September 2025, the FDA announced accelerated approval of Forzinity (elamipretide) as the first treatment for Barth syndrome in patients weighing at least 30 kg. According to the FDA’s announcement, the approval was based on improved knee extensor muscle strength, an intermediate endpoint that the agency considered reasonably likely to predict benefit, and a confirmatory randomised placebo-controlled trial is required. The FDA also reported that the most common side effects in clinical trials were mild-to-moderate injection site reactions, and that serious reactions have been reported.
How to read this
Three points matter for anyone interpreting the above.
- It is an approval for a specific indication, in a specific population, of a pharmaceutical product under medical supervision. It says nothing about unlicensed research material or about use in healthy people.
- Accelerated approval means the agency has asked for confirmatory evidence. It is not the same as a full demonstration of clinical benefit.
- Reports of side effects from the approved product describe a clinical setting and a specific formulation, and cannot be transferred to a laboratory vial.
This is also the right place to address queries such as “what are the side effects of SS-31 peptide” and “who should not take SS-31”. Those are use questions. Peptides Lab UK supplies SS-31 for laboratory research only and does not give advice on use in people. The FDA labelling and a prescriber are the authorities for the licensed product.
Practical notes for laboratories
- Name the compound fully in methods: sequence, salt form and supplier lot, since “SS-31” is used loosely.
- Check identity by mass spectrometry. The sequence includes a non-standard residue (Dmt), so confirmation matters more than for a simple natural-residue peptide. Batches from Peptides Lab UK are HPLC & COA Verified.
- Calculate concentrations on paper. The peptide calculator and our concentration and molarity guide cover the arithmetic.
- Match controls to the question. Mitochondrial endpoints such as respiration and membrane potential are sensitive to assay conditions; include vehicle and positive controls.
Designing mitochondrial experiments with a membrane-active peptide
Because SS-31 is proposed to act at a membrane, experiments with it need extra care. Respiration measured with a plate-based oxygen-consumption assay or a high-resolution respirometer is sensitive to cell density, substrate supply and the order of reagent additions, so report all of them. Membrane-potential dyes such as TMRM can themselves perturb mitochondria at higher concentrations, which means a dye-only control belongs in every run. Cationic peptides can adsorb to plastic and to serum proteins, so the effective concentration in a well may be lower than the nominal one; recording the vessel material and serum content helps others interpret the result. Test a concentration range rather than a single point, because membrane-active compounds can show biphasic behaviour, and normalise outputs to protein or cell number. Finally, report the lot and certificate, so that a later laboratory can compare like with like. None of this is specific to SS-31, but each point matters more when the proposed target is a lipid membrane.
Why an approval does not make a research vial a drug
It is worth dwelling on the regulatory point, because it is the one most often blurred. A medicine approval attaches to a specific product made to a specific specification, with defined manufacturing controls, sterility, impurity limits, stability data and labelling, and it covers a defined indication and population. A research-grade peptide is made and tested for a different purpose. It may share the amino-acid sequence with an approved drug, but it has not been through that product-level assessment, and nothing about the approval transfers to it. The same is true of the safety information in the label. For a laboratory, the useful consequence is modest and practical: the existence of a licensed form is a good reason to expect a rich literature to read, and no reason to assume a vial behaves like the licensed product.
Frequently asked questions
For the supplier-evidence side of this topic, see our best research peptides UK checklist and our guide to where to buy peptides in the UK.
What is another name for SS-31?
SS-31 is also called elamipretide (its International Nonproprietary Name), MTP-131 and Bendavia. The US brand name of the approved formulation is Forzinity. They all refer to the same tetrapeptide, D-Arg-Dmt-Lys-Phe-NH2.
What peptide is similar to SS-31?
Structurally, other Szeto-Schiller analogues such as SS-20 and SS-02. Mechanistically, mitochondrial-derived peptides such as humanin and MOTS-c are a different class that also relate to mitochondrial biology. Similar keywords do not mean similar mechanisms.
Is SS-31 approved as a medicine?
Elamipretide (Forzinity) received accelerated approval from the US FDA on 19 September 2025 for Barth syndrome in patients weighing at least 30 kg. That is a specific licensed product and indication; research-grade SS-31 is a different matter and is supplied for laboratory research only.
What are the side effects of SS-31 peptide?
Peptides Lab UK does not give advice on use in people. For the approved product, the FDA reported mild-to-moderate injection site reactions as the most common side effects in clinical trials, and serious reactions have been reported.
How does SS-31 work?
It is proposed to accumulate at the inner mitochondrial membrane and associate with cardiolipin. That is a hypothesis from the published literature; studies should state which mechanism they are testing.
Peptides Lab UK products are supplied for laboratory research use only, not for human or veterinary use. This article is educational and is not medical advice.